U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451652) titled 'Low Dose Epcoritamab Plus GemOx in R/R DLBCL' on Feb. 13.
Brief Summary: In this study, researchers are looking to determine whether Gemcitabine/Oxaliplatin plus a lower dose of Epcoritamab (12 mg) works to treat subjects with relapsed/refractory diffuse large B-cell lymphoma, who are candidates to autologous stem cell transplantation.
Study Start Date: Feb., 2026
Study Type: INTERVENTIONAL
Condition:
Relapsed/Refractory Diffuse Large B Cell Lymphoma
Intervention:
DRUG: Epcoritamab
Subjects will receive 2 step up doses of Epcoritamab (0.16 mg and 0.8 mg) followed by 12 mg weekly, for a total of three 21-day cycles (8 applicat...